Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has shared an update.
Shanghai Junshi Biosciences Co., Ltd. has reported that its seventeenth meeting of the fourth session of the board of directors was duly convened on 13 March 2026, with all 14 eligible directors in attendance and procedures confirmed as compliant with Chinese corporate law and the company’s articles. The board approved the 2025 annual work report, which will now be submitted to the general meeting, and reaffirmed the legality and validity of its resolutions, underscoring stable governance and regulatory transparency for shareholders.
The company also drew investors’ attention to several previously published announcements on matters including the use of proceeds, temporary liquidity replenishment, external guarantee quotas, profit distribution plans, a change in securities affairs representative and recognition of core technical personnel. Together, these disclosures provide a consolidated view of Junshi Biosciences’ capital deployment, risk management and talent strategy, offering stakeholders greater visibility into its operational and financial planning for 2025 and 2026.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$22.50 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a China-based biopharmaceutical company listed in both Shanghai and Hong Kong that focuses on the research, development and commercialization of innovative therapies. Its operations are governed by the PRC Company Law and its Articles of Association, with a board comprising executive, non-executive and independent non-executive directors overseeing strategic and regulatory matters.
Average Trading Volume: 3,152,085
Technical Sentiment Signal: Sell
Current Market Cap: HK$32.33B
Learn more about 1877 stock on TipRanks’ Stock Analysis page.